{
    "2019-12-27": [
        [
            {
                "time": "",
                "original_text": "业绩“虚胖”、盈利短板明显，白云山千亿元目标恐成空",
                "features": {
                    "keywords": [
                        "业绩",
                        "虚胖",
                        "盈利短板",
                        "白云山",
                        "千亿元目标"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "白云山子公司获36个药品再注册批件",
                "features": {
                    "keywords": [
                        "白云山",
                        "子公司",
                        "药品",
                        "再注册批件"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "白云山(00874)：附属收到药品再注册批件",
                "features": {
                    "keywords": [
                        "白云山",
                        "附属",
                        "药品",
                        "再注册批件"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "白云山(600332.SH)：子公司收到36个药品的《药品再注册批件》",
                "features": {
                    "keywords": [
                        "白云山",
                        "子公司",
                        "药品",
                        "再注册批件"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "白云山(600332.SH)：子公司获得11个品种药品补充申请批件",
                "features": {
                    "keywords": [
                        "白云山",
                        "子公司",
                        "药品",
                        "补充申请批件"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "白云山(00874.HK)获得复方南板蓝根颗粒等11个品种药品补充申请批件",
                "features": {
                    "keywords": [
                        "白云山",
                        "复方南板蓝根颗粒",
                        "药品",
                        "补充申请批件"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "白云山(00874.HK)：子公司奇星药业收到药品补充申请批件",
                "features": {
                    "keywords": [
                        "白云山",
                        "奇星药业",
                        "药品",
                        "补充申请批件"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}